# TREVENTIS Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/treventis

- Industry: Biotechnology
- Headquarters: US
- Website: www.treventis.com
- Total disclosed funding: $0.6M
- Latest round: Seed (Aug 10, 2009)
- Investors on record: 1

## About

TREVENTIS Corporation focuses on developing pharmaceutical compounds that address misfolded proteins, which are linked to neurodegenerative diseases. Their proprietary technology aids in designing targeted therapies for conditions like Alzheimer's disease and oncology.TREVENTIS Corporation was founded in 2008 in the US and specializes in the creation of pharmaceutical solutions for neurodegenerative diseases. The company was established by Christopher Barden, Donald Weaver, L. McIntosh, and William Wong. The company has closed a total of two deals, with the most recent occurring on September 18, 2013, when TREVENTIS secured a GRANT of USD 4.4 mn from Wellcome Trust. The total amount raised by the company is USD 0.55 mn.TREVENTIS Corporation specializes in designing and developing pharmaceutical compounds that target misfolded proteins, a significant factor in neurodegenerative diseases. Their proprietary Common Conformational Morphology (CCM) technology is essential for identifying druggable active sites in these proteins, allowing the rational design of small molecules aimed at treating conditions like Alzheimer's disease. TREVENTIS has established partnerships, notably with Takeda, to advance its lead program currently under development, targeting pharmaceutical companies and research institutions in North America and Europe engaged in neurodegenerative diseases and oncology.TREVENTIS Corporation generates revenue through strategic partnerships, particularly with prominent pharmaceutical companies such as Takeda. The business model includes revenue-sharing agreements, licensing deals for their CCM technology, and joint development programs designed to facilitate the commercialization of their drug candidates, with payments structured around milestones in drug development, research, clinical trials, and regulatory approvals.In September 2013, TREVENTIS Corporation received USD 4.4 mn from Wellcome Trust, aimed at supporting the advancement of their drug development initiatives. Future growth plans involve designing and launching new pharmaceutical products targeting misfolded proteins and expanding market presence in North America and Europe by targeting pharmaceutical companies and research institutions. These efforts are supported by recent funding aimed at accelerating the development of therapies in neurodegenerative diseases and oncology.

## Funding rounds

- Seed, Aug 10, 2009, $0.6M — BioAdvance

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed